EGFR and breast carcinoma: Thus, mutations in, for example, tumour protein p53 (TP53), phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha (PIK3CA), erb‐b2 receptor tyrosine kinase 2 (ERBB2), fibroblast growth factor receptor 3 (FGFR3), AT‐rich interaction domain 1A (ARID1A), epidermal growth factor receptor (EGFR), Neurofibromin 1 (NF1), retinoblastoma‐associated protein (RB1), breast cancer type 1 susceptibility (BRCA1), proto‐oncogene B‐Raf (BRAF) and RAF proto‐oncogene (RAF1) have been revealed [15, 16].